DOI: 10.25442/hku.29245022.v1
title: Supporting data for thesis "p19Arf-Based Senolytic Vaccine Improves Age-Associated Pathologies and Extends Healthspan in Aging Mouse Models"

description: The dataset includes all raw data from the results section of the thesis, as well as processed data and images. The dataset has been divided into 7 subfolders based on chapters. Within these subfolders, the data is further organized into multiple folders by figure, with most folders containing data for a single figure and a few containing data for multiple figures. To locate the data for a specific figure, simply find the corresponding folder. Most of the data has been processed using Excel, and statistical graphs were generated using GraphPad software. The detailed descriptions for each folder are shown as followed:​<b>​Supporting Data for Chapter 3.1​</b>​<br>The dataset provides molecular validation of p19Arf as a senescence-associated target through qPCR and Western blot analyses, demonstrating its upregulated expression in senescent cells. Complementary senescence-associated β-galactosidase staining further confirmed the role of p19Arf in promoting cellular senescence, establishing its relevance in aging biology.​<b>​Supporting Data for Chapter 3.2​</b>​<br>This dataset encompasses the design and preclinical evaluation of p19Arf-derived peptide vaccines, where ELISPOT assays were employed to screen immunogenic candidates. Comprehensive safety assessments, including histological examinations of major organs, verified the absence of adverse effects in vaccinated mice, supporting the vaccine's biocompatibility. The folder includes high-resolution histopathology images for detailed review.​<b>​Supporting Data for Chapter 3.3​</b>​<br>In vitro studies utilized induced senescence models to investigate the vaccine's mechanism, with lactate dehydrogenase release assays confirming that T cells from immunized mice selectively targeted senescent cells. These results validate the vaccine's capacity to mediate specific clearance of senescent cells while preserving healthy populations.​<b>​Supporting Data for Chapter 3.4​</b>​<br>Experiments in accelerated aging mouse models evaluated the vaccine's therapeutic potential, with longitudinal monitoring of physiological and molecular aging markers. Observations included mitigated age-related weight fluctuations, preserved cognitive function, and reduced oxidative stress, collectively indicating deceleration of aging phenotypes.​<b>​Supporting Data for Chapter 3.5​</b>​<br>Analyses in naturally aged mice assessed systemic aging parameters, revealing modulated expression of senescence-associated genes and inflammatory markers following vaccination. The data highlight the vaccine's ability to counteract age-associated molecular dysregulation in physiological aging contexts.​<b>​Supporting Data for Chapter 3.6​</b>​<br>Structural and functional assessments demonstrated improvements in musculoskeletal health, with microCT imaging revealing enhanced bone architecture and treadmill tests showing prolonged physical endurance. These findings underscore the vaccine's benefits in maintaining mobility and skeletal integrity during aging.​<b>​Supporting Data for Chapter 3.7​</b>​<br>Long-term efficacy studies confirmed sustained immune memory responses and significant lifespan extension in vaccinated cohorts. Persistent antigen-specific T cell activity and delayed mortality onset were observed, supporting the vaccine's durability and potential as an intervention for healthy aging.<br>